In this scenario, the endogenous endothelial nitric oxide synthase (eNOS) inhibitor NG,NG,dimethyl-L-arginine (ADMA) has gained interest as a potential marker of endothelial dysfunction positively correlated with risk factors for atherosclerosis and cardiovascular disease (CVD) under a broad range of circumstances [17–19]. This evidence concerns the gene NOS3 and cardiovascular disorder.